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Abstract
Chronic immune activation and inflammation (e.g., as manifest by production of type I interferons) are major determinants
of disease progression in primate lentivirus infections. To investigate the impact of such activation on intrathymic T-cell
production, we studied infection of the human thymus implants of SCID-hu Thy/Liv mice with X4 and R5 HIV. X4 HIV was
observed to infect CD3
2CD4
+CD8
2CXCR4
+CCR5
2 intrathymic T-cell progenitors (ITTP) and to abrogate thymopoiesis. R5
HIV, by contrast, first established a nonpathogenic infection of thymic macrophages and then, after many weeks, began to
replicate in ITTP. We demonstrate here that the tropism of R5 HIV is expanded and pathogenicity enhanced by upregulation
of CCR5 on these key T-cell progenitors. Such CCR5 induction was mediated by interferon-a (IFN-a) in both thymic organ
cultures and in SCID-hu mice, and antibody neutralization of IFN-a in R5 HIV-infected SCID-hu mice inhibited both CCR5
upregulation and infection of the T-cell progenitors. These observations suggest a mechanism by which IFN-a production
may paradoxically expand the tropism of R5 HIV and, in so doing, accelerate disease progression.
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Introduction
HIV disease progression is marked by chronic immune
activation associated with accelerated destruction of T cells in
the periphery and diminished production of new T cells from
progenitors in the thymus and elsewhere [1,2]. Although the
detection of X4 HIV as the predominant viral species in peripheral
blood is clearly associated with a higher risk of disease progression,
about half of patients progress to AIDS in the presence of R5
viruses alone [3,4] or with only the transient appearance of X4
virus [5]. Since it is just a small fraction of CD4
+ target cells that
express the CCR5 coreceptor [6], the mechanisms underlying
such intrinsic R5 virus pathogenicity remain unclear. Given the
association between high levels of T-cell activation and more rapid
disease progression in untreated HIV-infected individuals [7],
however, it is possible that such activation might induce the
upregulation of CCR5 and expand the tropism of R5 HIV to
include essential T-cell progenitors that are normally spared.
To address the hypothesis that R5 HIV infection might lead to
such an indirect expansion of tropism in vivo, we investigated the
course of R5 HIV infection in the SCID-hu Thy/Liv mouse
model of human T-cell production. This small animal model, in
which severe combined immunodeficient (C.B-17 SCID) mice are
implanted with human fetal thymus and liver under the kidney
capsule, supports multilineage human hematopoiesis, including T
lymphopoiesis, for periods up to one year [8] and represents a
venue in which to study the effects of HIV on human thymopoiesis
in vivo. After inoculation with X4 HIV, a key population of ITTPs
(CD3
2CD4
+CD8
2CXCR4
+CCR5
2) is rapidly infected and
destroyed, impeding thymocyte maturation and depleting the
implants of thymocytes within 4–5 weeks [9,10]. In contrast, rapid
destruction of the thymic organ is not observed after infection with
the R5 isolate Ba-L, which follows a biphasic process involving
nonpathogenic replication in medullary stromal macrophages
followed by cytopathic replication in thymocytes after 6 weeks of
infection [11]. CCR5 is expressed at much lower levels than
CXCR4 (,5% versus 30–40% of thymocytes) at all stages of T-
cell development in the thymus [6,12,13], and this may explain the
decreased pathogenicity of R5 HIV in that organ.
We demonstrate here that R5 HIV causes eventual depletion of
thymocytes that is associated with de novo IFN-a-mediated
upregulation of CCR5 on ITTP, rendering these key progenitor
cells permissive for R5 HIV infection and depletion. Moreover, we
show that monoclonal antibody (MAb) neutralization of IFN-a in
SCID-hu Thy/Liv mice inhibits CCR5 induction after HIV
infection and prevents infection of ITTP with R5 HIV. The
observation that IFN-a may be a driving force behind expanded
HIV tropism in vivo offers a proximal mechanism for the
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and suggests that immunomodulatory agents that suppress the
production or the effects of IFN-a may serve to slow disease
progression in the HIV-infected host.
Results
HIV infection is associated with CCR5 induction and
infection of thymocyte progenitors
The human thymus implants of SCID-hu Thy/Liv mice were
inoculated with the X4 HIV clone NL4-3, the R5 HIV isolate Ba-
L, or a chimeric R5 clone of NL4-3 containing the V1-V3 env
regions of Ba-L (81A) and monitored for viral replication and
thymocyte depletion at 21 and 42 days. As expected from our
previous work in the Thy/Liv model [11,14,15,16], viral
replication resulted in time-dependent increases in implant HIV
RNA, p24, Gag-p24
+ thymocytes, and MHC class I expression on
CD3
intCD4
+CD8
+ (double-positive, DP) thymocytes (Figure 1A).
Viral replication was accompanied by time-dependent decreases in
implant cellularity, thymocyte viability, percentage of DP
thymocytes, and CD4/CD8 ratio (Figure 1B) that were more
rapid and of greater magnitude for X4 than for R5 HIV, a finding
consistent with the far greater of expression of CXCR4 than
CCR5 on human thymocyte subpopulations [6].
The slow butevident pathogenicity ofR5 HIV maybe dependent
upon inductive events that take place after infection. For instance,
progressivesequencevariation intheenv genemay enablea ‘‘switch’’
of envelope glycoproteins to a pathogenic X4 phenotype. Alterna-
tively, R5 viral pathogenesis may proceed in a time-dependent
mannerthroughinfection ofITTP,whichconstitutea minorbutkey
thymocyte progenitor subpopulation, in a manner analogous to X4
thymic pathogenesis [10]. Since we have previously found that an
R5-to-X4 phenotypic switch is not detectable during thymic
infection with Ba-L [11], we more closely evaluated the possibility
that ITTP, which are normally CCR5-negative [6,12], might be
infected at some time point after virus inoculation.
Intracellular Gag-p24 staining in concert with surface staining
for CD3, CD4, and CD8 revealed that ITTP were infected by Ba-
L and 81A at day 42 but not day 21 (Figure 1C). This finding was
unexpected because ITTP do not normally express CCR5 [6] and
were thus not considered targets of R5 HIV infection, in marked
contrast to the susceptibility of ITTP to X4 HIV infection as a
consequence of high-level expression of CXCR4 [6]. Reasoning
that CCR5 expression might be indirectly induced by HIV
infection, we evaluated CCR5 expression on thymocyte subpop-
ulations after HIV inoculation and found, at day 42 but not
day 21, statistically significant increases in the percentage of
CCR5-expressing ITTP [to 6.461.5% (P=0.017) for Ba-L
and to 3.260.2% for 81A (P=0.001) versus a mean of
1.360.2% for mock-infected implants] (Figure 1D and E). Less
dramatic, but still statistically significant increases in CCR5-
positive CD3
+CD4
2CD8
+ (single-positive, SP8) thymocytes were
also observed, as has been reported previously in NOD/SCID-hu
BLT mice infected intravaginally with HIV and attributed to a
heightened state of immune activation [17]. Significant increases
in the percentage of CCR5
+ ITTP were also observed in X4 NL4-
3-infected implants (Figure 1D). Treatment of SCID-hu Thy/Liv
mice with 3TC (lamivudine) inhibited the induction of CCR5 on
thymic progenitors and prevented Ba-L-mediated thymocyte
depletion (data not shown). These results indicate that induction
of CCR5 in HIV-infected Thy/Liv implants occurs in a time-
dependent manner that is dependent on active HIV (R5 or X4)
replication.
CCR5 expression on ITTP is induced by IFN-a
Previous reports have demonstrated that CCR5 expression can
be increased on several cell types after treatment with cytokines
including IL-2 [18], IL-4 [19], IL-10 [20,21], IL-15 [22], TGF-b
[23], and IFN-c [24], and with HIV Tat [25]. When human
thymic organ cultures were incubated with these and other
cytokines, significant induction of CCR5 expression on human
thymocytes was only observed after treatment with IFN-a
(Figure 2A). Analysis of CCR5 expression on thymocyte
subpopulations demonstrated statistically significant upregulation
on ITTP (Figure 2B), the same key subpopulation found to
upregulate CCR5 in the HIV infected thymic implant and which
we have previously reported to express the IFN-a/b receptor [26].
This receptor is expressed at high levels on ITTP and at
progressively lower levels on more mature thymocytes (e.g., DP,
SP4, and SP8 thymocytes) [26]. The ability of IFN-a to induce
expression of CCR5 is consistent with the presence of STAT-
binding sites at nt 255 and 2116 in the CCR5 promoter;
mutation of the proximal STAT site nearly abolishes promoter
activity [27].
To determine whether IFN-a can induce expression of CCR5
on ITTP in vivo, we treated groups of SCID-hu Thy/Liv mice in
three separate cohorts (A, B, and C) with IFN-a2b (Intron A or
pegylated interferon alfa-2b) by once-daily intraperitoneal (i.p.)
injection for 6 or 13 days. Significant increases in the percentage of
CCR5
+ ITTP were observed at both time points, normalizing to
pretreatment levels after discontinuation of IFN-a (Figure 2B and
C). Treatment with IFN-a for 13 days had no effect on the
percentage and absolute number of ITTP or other more mature
thymocyte subpopulations present in the implants (data not
shown), so it is unlikely that the increase in CCR5
+ cells is the
result of either IFN-a-mediated apoptosis of CCR5-negative ITTP
or an increased rate of CCR5
+ ITTP cell division. Of note, the
percentage of CCR5
+ ITTP in IFN-a-treated mice (means in the
three cohorts: 6–20%, range: 3–37%) (Figure 2B and C) tended to
be higher than that found in Ba-L-infected mice at day 42 (mean:
6%, range: 0–12%) (Figure 1D and E), a difference that may be
Author Summary
Human immunodeficiency virus (HIV), a lentivirus, is the
causative agent of AIDS. Chronic immune activation and
inflammation are major determinants of disease progres-
sion in primate lentivirus infections and are associated
with the production of type I interferon. To investigate the
impact of type I interferon on HIV infection, we studied the
human thymus implants of SCID-hu Thy/Liv mice infected
with HIV that uses either CXCR4 (X4 HIV) or CCR5 (R5 HIV)
as a coreceptor. X4 HIV was observed to infect T-cell
progenitors in the thymus and to disrupt T-cell production
by that organ. R5 HIV, by contrast, first established a
nondisruptive infection of thymic macrophages and then
began to infect intrathymic T-cell progenitors. We report
here that the tropism of R5 HIV is expanded and T-cell
disruption enhanced by increased expression of CCR5 on
these key T-cell progenitors. Such CCR5 induction was
mediated by interferon-a (IFN-a) in both thymic organ
cultures and in SCID-hu mice. Moreover, antibody neutral-
ization of IFN-a in R5 HIV-infected SCID-hu mice inhibited
both CCR5 upregulation and infection of the T-cell
progenitors. These observations suggest a mechanism by
which IFN-a may paradoxically expand the tropism of R5
HIV and accelerate disease progression.
IFN-a-Induced CCR5 and HIV Tropism
PLoS Pathogens | www.plospathogens.org 2 February 2010 | Volume 6 | Issue 2 | e1000766Figure 1. HIV infection is associated with increases in CCR5 expression and detection of R5 HIV in thymocyte progenitors. Increases
in (A) viral load (as determined by implant viral RNA, p24, and Gag-p24
+ thymocytes) and MHC-I expression, (B) thymocyte depletion (as determined
by total cellularity, the percentage of viable thymocytes and of DP thymocytes, and the CD4/CD8 ratio), (C) Gag-p24
+ thymocyte subpopulations and
(D) CCR5 expression by thymocyte subpopulations in Thy/Liv implants with time after inoculation with 1,000 TCID50 HIV NL4-3, Ba-L, or 81A. Data are
presented as mean6SEM for n=7 or 8 mice per time point and virus, and asterisks indicate P,0.05 compared to mock-infected mice (day 0 data) by
the Mann-Whitney U test. (E) CCR5 expression on ITTP from representative mock- and Ba-L-infected (day 42) implants. FMO is the fluorescence-minus
one plot used for CCR5 gating, and percentages of CCR5
+ ITTP are indicated. DP are ‘‘double-positive’’ CD3
intCD4
+CD8
+ thymocytes, SP4 are ‘‘single-
positive’’ CD3
+CD4
+CD8
– thymocytes, and SP8 are ‘‘single-positive’’ CD3
+CD4
+CD8
– thymocytes.
doi:10.1371/journal.ppat.1000766.g001
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PLoS Pathogens | www.plospathogens.org 3 February 2010 | Volume 6 | Issue 2 | e1000766Figure 2. IFN-a induces CCR5 expression on thymocyte progenitors both in vitro and in vivo. (A) Thymus organ cultures were incubated
in triplicate with the indicated cytokines or with Tat for 3 days, and dispersed cells were stained with MAbs against CD3, CD4, CD8, and CCR5 for flow
cytometry. Only treatment with IFN-a significantly increased CCR5 expression on thymocytes (left), and the ITTP subset showed the greatest increase
(right). Data are representative of three independent experiments. TN are ‘‘triple-negative’’ CD3
2CD4
2CD8
2 thymocyte progenitors. (B) SCID-hu Thy/
Liv mice from three cohorts (A, B, and C) were treated with IFN-a or sterile water (mock) by once-daily i.p. injection for 6 or 13 days, and Thy/Liv
implants were collected and stained one day after the last injection or after 7 additional days of no treatment. IFN-a significantly increased the
percentage of CCR5
+ ITTP, which normalized within 7 days of treatment cessation. Asterisks indicate P,0.05 compared to mock-treated cultures or
mice by the Mann-Whitney U test. (C) CCR5 expression on ITTP from representative mock- and IFN-a-treated (cohort C) mice. FMO is the fluorescence-
minus one plot used for CCR5 gating, and percentages of CCR5
+ ITTP are indicated. The mean fluorescence intensity of the CCR5
+ ITTP is shown in
the histogram below each dot plot.
doi:10.1371/journal.ppat.1000766.g002
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+
progenitors.
The presence of CCR5
+ ITTP is highly correlated with viral
load and thymocyte depletion after HIV infection
To examine more closely the relationship between CCR5
+
induction on ITTP, thymic organ infection, and thymocyte
depletion, we studied two additional SCID-hu Thy/Liv cohorts
(D and E) inoculated with Ba-L plus two cohorts (G and H)
inoculated with the R5 isolate, CC1/85. Data for these cohorts
were analyzed together with the data obtained from the Ba-L and
81A-infected mice shown in Figure 1 (cohort F). Implant viral
loads measured 42–49 days after inoculation were within 1.0 log10
across all six infected groups (means of 4.4–5.4 log10 copies HIV
RNA and 80–800 pg p24 per 10
6 cells) (Figure 3A). For the two
additional SCID-hu cohorts inoculated with Ba-L (D and E),
implants collected at much later time points (up to one year) after
inoculation showed progressively more severe thymocyte deple-
tion, while mock-infected implants remained intact with ,80%
DP thymocytes (Figure 3B). As we have reported previously [11],
such depletion became noticeable 6 weeks after inoculation with
Ba-L; we accordingly focused on implants collected from the five
Figure 3. Thymocyte depletion and CCR5 induction on ITTP in six SCID-hu Thy/Liv mouse cohorts infected with R5 HIV Ba-L, 81A, or
CC1/85. (A) Implant viral RNA and p24 42–49 days after inoculation. Data for cohort F (81A) are from Figure 1. (B) Time course of DP thymocyte
depletion in Ba-L-infected cohorts D and E. (C) Implant cellularity, thymocyte viability, and percentage of DP thymocytes and (D) percentage of CCR5-
expressing and Gag-p24
+ ITTP for each of the five cohorts 42–49 days after inoculation. *P,0.05, **P,0.01 compared to mock-infected mice by the
Mann-Whitney U test.
doi:10.1371/journal.ppat.1000766.g003
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Although the decreases in implant cellularity, thymocyte viability,
and percentage of DP thymocyte were often not statistically
significant when individual experiments were compared (likely the
result of the small number of mock-infected mice), animals in the
R5 HIV-infected cohorts showed a trend towards decreases in
each of these parameters. Concomitantly, there were increases in
the percentage of CCR5
+ ITTP compared to mock-infected mice,
and the percentages of CCR5
+ ITTP were comparable to the
percentages of ITTP that were Gag-p24
+ (Figure 3D).
To better document the relationship between CCR5 expression
on ITTP and thymocyte depletion, data for each individual
implant were plotted to show the correlation between the
percentage of CCR5
+ ITTP and viral load (Figure 4A) as well
as the percentage of CCR5
+ ITTP and thymocyte depletion
(Figure 4B). Not only are the correlations highly significant for
infected implants in statistical terms (e.g., P,0.0001 for CCR5
+
ITTP versus both Gag-p24
+ ITTP and thymocyte viability), but
the proportion of CCR5
+ ITTP corresponds closely to that of
infected ITTP (Figure 4A). In contrast, there was no correlation
between CCR5
+ ITTP and markers of thymocyte depletion for
mock-infected implants (Figure 4B). Accordingly, it is highly likely
that induction of CCR5 expression on ITTP is a causal event
precipitating thymocyte depletion after HIV infection.
Neutralization of IFN-a in R5, but not X4, HIV-infected
SCID-hu mice inhibits CCR5 upregulation and infection of
ITTP
To show definitively that upregulation of CCR5 on ITTP was
mediated by IFN-a we treated three cohorts (I, J, and K) of SCID-
hu Thy/Liv mice with a broadly neutralizing mouse MAb against
multiple human IFN-a subtypes. Mice were treated by three times
weekly i.p. injection, beginning 2 days before Ba-L, 81A, or NL4-3
inoculation and continuing until implant collection. For mice
infected with Ba-L, neutralization of IFN-a was found to result in a
lower percentage of CCR5
+ ITTP (P,0.05 in cohort I and
P,0.01 in cohort J), a lower percentage of Gag-p24
+ total live
thymocytes (P,0.05 in both cohort I and J), and a lower
percentage of Gag-p24
+ ITTP (P,0.01 in cohort I and J)
(Figure 5). In cohort K, we directly compared the effects of IFN-
a neutralization on HIV 81A (R5) and NL4-3 (X4) infection. This
experiment was carried out with the expectation that infection of
ITTP would be inhibited after 81A, but not after NL4-3,
inoculation. We found that this was indeed the case: there was a
93% reduction (P=0.005) in Gag-p24
+ ITTP after IFN-a-
treatment in 81A-infected mice yet an insignificant 25% reduction
(P=0.501) in Gag-p24
+ ITTP in treated NL4-3-infected mice.
This was accompanied by expected reductions in CCR5
+ ITTP
for both viruses (89% reduction for 81A; P=0.004 and 67%
reduction for NL4-3; P=0.083). Given our previous data showing
that infection of ITTP leads to interruption of thymopoiesis [10],
these results indicate that IFN-a-induced upregulation of CCR5
on ITTP is likely to result in diminished production of T cells from
the thymus.
Discussion
R5 isolates of HIV have been associated with disease
progression in HIV-infected individuals [28]. Likewise, as we
have shown here, R5 HIV can be pathogenic in the SCID-hu
Thy/Liv model of human thymopoiesis. Even though there is little
CCR5 expression in the human thymus, R5 HIV was found to
induce delayed but significant depletion of developing DP
thymocytes and reduction in implant cellularity, and progression
of R5 infection was found to correlate with the induction of CCR5
Figure 4. Correlation between CCR5 induction on ITTP, HIV replication, and thymocyte depletion. The percentage of CCR5-expressing
ITTP is highly correlated with (A) viral load and (B) thymocyte depletion for each individual infected Thy/Liv implant in the six SCID-hu mouse cohorts
shown in Figure 3. The percentage of control values for total cells per implant was calculated by dividing total cells per HIV-infected implant by the
mean value for mock-infected implants from the same cohort to adjust for cohort-dependent variation in implant size.
doi:10.1371/journal.ppat.1000766.g004
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turn, is mediated by IFN-a both in vitro and in vivo. This finding
is in contrast to a previous report showing that R5 HIV infection
of thymic organ cultures induced CCR5 on CD4
+ thymocytes
through the production of IL-10 and TGF-b [29]. The ability of
HIV to induce expression of its own coreceptor through the major
antiviral cytokine, IFN-a likely evolved to dampen this antiviral
defense mechanism, a counterbalancing act that has been likened
to a de ´tente through which virus and host achieve conditions for
coexistence [30].
The above results indicate that expanded tropism of R5 HIV in
the infected human thymus (to ITTP and DP thymocytes) is a
secondary event that occurs after the induction of IFN-a
production, most likely from plasmacytoid dendritic cells (pDC).
These cells function as part of the innate immune response by
secreting large quantities of IFN-a after contact or infection with a
wide range of viruses, including HIV [31,32,33]. IL-3Ra
+ pDC
reside in the medulla of the human thymus [34], and we have
previously shown that these cells produce IFN-a in response to
HIV infection in both human thymic organ culture and in SCID-
hu Thy/Liv mice [26]. Intrathymic pDC express both CXCR4
and CCR5 and are themselves targets for HIV replication [35],
although it is not known if infection of these cells plays a role in
IFN-a secretion. In sum, interactions between R5 HIV and pDC
might lead indirectly to upregulation of CCR5 on cells that are
normally not permissive for R5 infection. If so, these data point to
a critical role for pDC-mediated IFN-a secretion in R5 HIV
pathogenesis in the thymus of the SCID-hu mouse.
There is a low frequency of CCR5
+ pDC in the
CD3
2CD4
+CD8
2 thymocyte population (unpublished observa-
tions), but we believe our results are due to upregulation of CCR5
on the T-lineage component of this population for the following
reasons: First, in vitro IFN-a treatment results in upregulation of
CCR5 on ITTP and DP (Figure 2A), cell populations that are T-
lineage and that express high levels of the IFN-a/b receptor [26].
In vivo, the same phenomenon occurs (Figure 2B). Second, The
fraction of CCR5
+ ITTP is similar to the fraction of p24
+ ITTP
(Figure 3D), and there is a significant relationship between the two
when analyzed in a large number of animals (Figure 4A). Finally,
neutralizing anti-IFN-a antibody blocks the upregulation of CCR5
on the ITTP population (Figure 5). All of these data (especially the
data in Figure 5) are most consistent with IFN-a induction of
CCR5 on the CD3
2CD4
+CD8
2CCR5
2 ITTP and the
CD3
+CD4
+CD8
+CCR5
2 DP populations, both of which are
permissive for infection and replication of HIV.
These data also illustrate the importance of cell-cell interactions
that can occur in lymphoid tissue after HIV infection with
profound influence on the course of disease progression and that
are not easily replicated in dispersed cell cultures. In addition,
available in vitro culture systems do not persist for the periods of
time required to measure the impact of these interactions on HIV
pathogenesis. The observations in this study thus underscore the
need for a closer evaluation of the dynamics of HIV infection
within lymphoid organs and provide experimental justification for
such tissue analysis within HIV-infected human subjects.
The finding that IFN-a can enhance HIV infectivity is
surprising, especially given the potent antiviral activity against
HIV we and others have reported in IFN-a-treated thymic organ
cultures [26,36]. These counterposing effects of IFN-a may occur
simultaneously in pDC-containing tissue, thereby contributing to
the slow progression of thymocyte depletion usually seen after R5
infection. Persistently high levels of IFN-a and of IFN-inducible
genes are associated with more rapid disease progression in SIV-
infected macaques [37,38,39]. In contrast, nonpathogenic SIV
infections are associated with transient IFN-a responses, possibly
due to the inability of the virus to activate pDC [40]. There is
likely a complicated set of kinetics at play during HIV infection of
Figure5.NeutralizationofIFN-a inhibitsCCR5inductionandHIV
infection of ITTP after R5 HIV, but not after X4 HIV, inoculation.
SCID-hu Thy/Liv mice infected (or not) with Ba-L (R5), 81A (R5), and NL4-3
(X4) were treated (or not) with IFN-a-neutralizing MAb (500 mge v e r y
other by i.p. injection) in three independent experiments. Columns
representmeans and opencircles individual animals 43daysafter Ba-L,63
days after 81A, and 21 days after NL4-3 inoculation. *P,0.05, **P,0.01
compared to infected untreated mice by the Mann-Whitney U test.
doi:10.1371/journal.ppat.1000766.g005
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of viral replication and spread; the rate of induction of IFN-a in
pDC; the rate of upregulation of CCR5 on thymocytes that
express the IFN-a/b receptor; the rate at which these cells are
infected and destroyed by R5 HIV; the rate at which they are
replenished from earlier, CCR5
2 progenitors; and, not least, the
rate at which more mature DP thymocytes are depleted. We
presume that the late events observed after HIV infection
represent a sum total of these and other counterposing rates,
resulting eventually in complete depletion of double-positive
thymocytes (e.g., by day 300 in Figure 3B).
IFN-a has been shown to inhibit thymic T-cell differentiation in
both the mouse [41] and human [42]. IFN-a-mediated inhibition
of T-cell development may have also contributed to the depletion
of thymocyte subsets observed in this study; however, we found
that treatment of the mice with IFN-a for 13 days had no effect on
the percentage and absolute number of ITTP or other more
mature thymocyte subpopulations present in the Thy/Liv
implants. It is possible that more prolonged exposure of the
implants to IFN-a over months of HIV infection may have more
deleterious cumulative effects on T-cell maturation than relatively
short-term IFN-a treatment.
The role of chemokine coreceptor utilization in HIV disease
progression has been studied extensively. The switch of viral
phenotype from R5 to X4 has a profound and negative effect on
absolute CD4 cell counts [43] and has been implicated as a
determining factor in accelerated disease progression [5]. Howev-
er, it appears that R5 HIV [28] and SIV [44] have the capacity to
be pathogenic in their own right. HIV can also evolve in vivo with
increased affinity for CCR5, thus acquiring the ability to infect
cells expressing low levels of the coreceptor and potentially
increasing pathogenicity [45,46]. We present evidence here that
CCR5 induction resulting from IFN-a secretion by pDC plays a
significant role in the pathogenesis of R5 HIV in the human
thymus implant of the SCID-hu Thy/Liv mouse. Given the close
structural and functional similarities between this model and the
intact human thymus [8] as well as prior evidence that HIV can
infect the thymus in humans [47,48,49,50,51], it is likely that these
observations are relevant not only to the HIV-infected child with
abundant thymic tissue but also to the HIV-infected adult, in
whom residual thymic function can continue to play a role in the
de novo production of naı ¨ve T cells [1].
Since pDC are resident throughout the lymphoid system and
migrate to inflamed lymph nodes [52], the expansion of R5 HIV
tropism described here in the human thymus may also occur in
other organs of the hematolymphoid system. Indeed, recent data
indicate that IFN-a treatment causes significant increases in
CCR5 mRNA expression in PBMC cultures from both HIV-
infected and uninfected individuals [53,54], and IFN-a treatment
of patients with uveitis resulted in increases of CCR5 expression
on peripheral blood CD4
+ T cells [55]. Even if these events are
restricted to thymic pDC, residual thymic function that persists in
some adults with HIV disease [1] might thereby be abrogated.
Alone or together, such interactions between HIV, pDC, and
normally CCR5-negative target cells might underlie disease
progression induced by R5 viruses in vivo.
Materials and Methods
Viruses
The following reagents were obtained through the AIDS
Research and Reference Reagent Program, Division of AIDS,
NIAID, NIH: pNL4-3 [56] from Dr. Malcolm Martin, HIV-1Ba-L
[57] from Dr. Suzanne Gartner, Dr. Mikulas Popovic and Dr.
Robert Gallo, and p81A-4 [58] (Cat#11440) from Dr. Bruce
Chesebro. CC1/85 [59] was generously provided by Drs. Shawn
Kuhmann and John Moore. Ba-L is a low-passage isolate that has
been propagated exclusively in human monocyte/macrophages
[57], and CC1/85 is a well-characterized patient isolate that has
also been minimally lab adapted [59,60]. Working stocks of NL4-3
and 81A were prepared by lipofectamine (Invitrogen) transfection
of 293T cells and collection of supernatants on day 2. Ba-L stock
was generated in monocyte-derived macrophages with the
supernatant collected on day 8, and CC1/85 stock was generated
in phytohemagglutinin (PHA)-activated peripheral blood mono-
nuclear cells (PBMC) with the supernatants collected on day 4.
Virus stocks were titrated by limiting dilution for 50% tissue
culture infectious doses (TCID50) in PHA-activated PBMC with
p24 detection by ELISA on day 7 as previously described [61].
HIV infection of SCID-hu Thy/Liv mice
Human fetal thymus and liver were obtained through services
provided by a nonprofit organization (Advanced Bioscience
Resources) in accordance with federal, state, and local regulations.
Coimplantation of thymus and liver pieces under the kidney
capsule to generate SCID-hu Thy/Liv mice and inoculation of the
Thy/Liv implants with HIV was performed as described [14,62].
Male C.B-17 SCID (model #CB17SC-M, homozygous, C.B-Igh-
1
b/IcrTac-Prkdc
scid) mice were obtained at 6–8 weeks of age from
Taconic, and cohorts of 50–60 SCID-hu Thy/Liv mice were
implanted with tissues from a single donor. Implanted mice were
maintained in a barrier facility under pathogen-free conditions
and inoculated 18 weeks after implantation with 50 ml of stock
virus (1,000 TCID50) or conditioned medium from PBMC cultures
(mock infection) by direct injection into the implant. All
procedures with mice were approved by the UCSF Institutional
Animal Care and Use Committee. The Thy/Liv implants were
collected from euthanized mice at the indicated time points,
placed into sterile PBS-FBS, and dispersed through nylon mesh
into a single cell suspension. Cells were counted and processed for
p24 ELISA, branched DNA assay, and flow cytometry as
previously described [14,15].
Flow cytometry
Dispersed implant cells were stained with MAbs against CD3,
CD4, CD8, MHC class I, CCR5, and intracellular Gag-p24.
Pellets containing 10
6 cells were resuspended in 50 ml of a MAb
mixture containing phycoerythrin cyanine dye CY7-conjugated
anti-CD4 (BD Biosciences), phycoerythrin cyanine dye CY5.5-
conjugated anti-CD8 (Caltag Laboratories), allophycocyanin
cyanine dye CY7-conjugated anti-CD3 (eBiosciences), allophyco-
cyanin-conjugated anti-CD195 (CCR5, clone 2D7) (BD Biosci-
ences), and phycoerythrin-conjugated anti-W6/32 (DakoCytoma-
tion) in PBS containing 0.8 mg/ml human IgG (Biodesign
International). Cells from one implant were also stained with
conjugated, isotype-matched antibodies to control for nonspecific
antibody binding. Cells were incubated for 30 min in the dark and
washed two times with PBS/2% FBS. Cells were resuspended in
200 ml of a fixation/permeabilization mixture containing 1.25%
human IgG (Biodesign International), 1.2% paraformaldehyde
(Sigma), and 0.5% polyoxyethylenesorbitan (Tween 20, Sigma) in
PBS/2% FBS. Cells were incubated for 60 min in the dark,
washed two times with PBS/2% FBS, and then resuspended in
50 ml of PBS containing fluorescein isothiocyanate-conjugated
anti-p24 (Beckman Coulter) and 0.8 mg/ml human IgG (Biode-
sign International). In addition, a ‘‘fluorescence minus one’’
(FMO) control was prepared in which the anti-p24-FITC was
omitted from the antibody mixture to allow for discrimination of
IFN-a-Induced CCR5 and HIV Tropism
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+ from Gag-p24
2 cells. Cells were incubated for 30 min
in the dark, washed twice with PBS/2% FBS, resuspended in
200 ml of PBS/2% FBS in 1.5-ml tubes, and analyzed on an LSR
II (BD Biosciences) with FlowJo software (Tree Star). Optimization
of fluorescence compensation for correction of fluorescence
spectral overlaps emitted from the fluorescent conjugated
antibodies was achieved by staining cells with each antibody
alone plus anti-mouse Ig kappa chain and negative control BD
CompBeads (BD Biosciences), as directed by the manufacturer.
After collecting 100,000 total cell events, percentages of marker-
positive (CD4
+, CD8
+, and DP) thymocytes in the implant samples
were determined by first gating on a live lymphoid cell population
identified by forward- and side-scatter characteristics and then by
CD3 expression. In addition, the fraction of cells positive for Gag-
p24 and CCR5 was determined for all thymocyte subpopulations
in each implant (Figure S1). W6/32-positive mean fluorescence
intensity (MFI) of DP thymocytes was determined for each sample,
and CD4/CD8 ratios were calculated by dividing the percentage
of CD4
+ cells by the percentage of CD8
+ cells for each individual
implant.
Treatment of SCID-hu Thy/Liv mice with IFN-a and IFN-a
neutralizing MAb
SCID-hu Thy/Liv mice from three cohorts (A, B, and C) were
treated with 10
6 IU recombinant interferon alfa-2b (Schering),
10 mg pegylated interferon alfa-2b (Schering), or sterile water by
once-daily i.p. injection for 6 or 13 days. Implants were collected
and stained for flow cytometry either 1 or 7 days after the last IFN-
a injection. SCID-hu Thy/Liv mice from three cohorts (I, J, and
K) were treated with a mouse MAb with broadly neutralizing
activity against multiple human IFN-as (clone 9F3.18.5 [63],
500 mg every other day by i.p. injection) kindly provided by Drs.
Andrew C. Chan and Kerstin Schmidt (Genentech) beginning 2
days before implant injection with Ba-L or 81A. The 9F3 MAb
does not neutralize IFN-b [63].
Cytokine treatment of human thymic organ cultures
Fetal thymus was dissected into small pieces and plated on
sterile filters (Millipore) placed on gelatin sponges (Pharmacia and
Upjohn) in 700 ml Yssel’s medium containing 1% human serum
(Gemini Bio-Products) in 24-well plates. Cultures were incubated
in the presence of various cytokines or HIV Tat at concentrations
shown previously to induce CCR5 upregulation, e.g., at 10 ng/ml
for IL-10 [21], IL-15 [22], HIV Tat [25], and TGF-b [23]; 20 ng/
ml for IL-4 [19] and IFN-c [24]; and 20 IU/ml for IL-2 [18]. In
the case of IFN-a, a dose of 1,000 IU/ml was selected on the basis
of dose-ranging experiments, although CCR5 upregulation was
observed at lower (300 IU/ml) IFN-a concentrations (data not
shown). Cytokine-treated thymus cultures were dispersed after 3
days, and cells were stained with MAbs to CD3, CD4, CD8, and
CCR5 for flow cytometry as described above.
Statistical analysis
Results are expressed as means6SEM. Nonparametric statisti-
cal analysis was performed by use of the Mann-Whitney U test
(StatView 5.0, Abacus Concepts), and correlation P values were
generated by the correlation Z test (StatView).
Supporting Information
Figure S1 Gating of thymocyte subpopulations and determina-
tion of CCR5
+ and Gag-p24
+ thymocytes in Thy/Liv implants.
After collecting 100,000 total cell events, percentages of marker-
positive (CD4
+, CD8
+, and DP) thymocytes in the implant samples
were determined by first gating on a live lymphoid cell population
identified by forward- and side-scatter characteristics and then by
CD3 expression. In addition, the fraction of cells positive for Gag-
p24 and CCR5 was determined for all thymocyte subpopulations
in each implant. W6/32-positive mean fluorescence intensity
(MFI) of DP thymocytes was determined for each sample, and
CD4/CD8 ratios were calculated by dividing the percentage of
CD4
+ cells by the percentage of CD8
+ cells for each individual
implant. Data shown is for HIV Ba-L-infected SCID-hu mouse
#39 (Figure 1E).
Found at: doi:10.1371/journal.ppat.1000766.s001 (0.90 MB PDF)
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